KS Lee - Publications, H-index & Citations

KS Lee

Monash University Malaysia

22H指数

266论文数

1.8K被引数

收录论文 33

发表时间

Feasibility of a deep learning-based diagnostic platform to evaluate lower urinary tract disorders in men using simple uroflowmetry

EUROPEAN UROLOGY

IF25.2

2021-06-01

PREAI

Bang, S.; Han, D. H.; Jeon, H. G.; Baek, M.; Cho, B. H.; Lee, K-S

Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation

ANNALS OF ONCOLOGY

IF65.4

2020-11-01

OAAI

Im, S-A.; Cortes, J.; Lipatov, O.; Goncalves, A.; Lee, K-S.; Schmid, P.; Tamura, K.; Testa, L.; Witzel, I.; Ohtani, S.; Zambelli, S.; Harbeck, N.; Andre, F.; Dent, R.; Lin, J.; Karantza, V.; Mejia, J. A.; Winer, E. P.

Exploratory biomarker analysis from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer(MBC): Korean cancer study group trial (KCSG BR13-11)

CANCER RESEARCH

IF16.6

2019-02-15

PREAI

Kim, J-Y; Lee, E. J.; Park, K. H.; Im, S-A; Kim, S-B; Sohn, S. H.; Lee, K. S.; Chae, Y. S.; Lee, K. H.; Kim, J. H.; Im, Y-H; Kim, T-Y; Lee, K-H; Ahn, J-H; Kim, G. M.; Park, I. H.; Lee, S. J.; Han, H. S.; Kim, S. H.; Jung, K. H.; Park, Y. H.

Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment

CANCER RESEARCH

IF16.6

2019-02-15

PREAI

Sim, S. H.; Park, I. H.; Jung, K. H.; Kim, S-B; Ahn, J-H; Lee, K-H; Im, S-A; Im, Y-H; Park, Y. H.; Sohn, J. H.; Kim, Y. J.; Lee, S.; Kim, H-J; Chae, Y. S.; Park, K-H; Nam, B-H; Lee, K. S.; Ro, J.

Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results

CANCER RESEARCH

IF16.6

2019-02-15

PREAI

Crown, J.; Sablin, M-P; Cortes, J.; Bergh, J.; Im, S-A; Lu, Y-S; Martinez, N.; Neven, P.; Lee, K. S.; Morales, S.; Perez-Fidalgo, J. A.; Adamson, D.; Goncalves, A.; Prat, A.; Jerusalem, G.; Schlieker, L.; Espadero, R-M; Bogenrieder, T.; Huang, D. Chin-Lun; Schmid, P.

MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

CANCER RESEARCH

IF16.6

2018-02-15

PREAI

Schmid, Peter; Zaiss, Matthias; Harper-Wynne, Catherine; Ferreira, Marta; Dubey, Sidharth; Chan, Stephen; Makris, Andreas; Nemsadze, Gia; Brunt, Adrian M.; Kuemmel, Sherko; Cabrero, Isabel Ruiz; Perello, Antonia; Kendall, Anne; Brown, Janet; Kristeleit, Hartmut; Conibear, John; Saura, Cristina; Grenier, Julien; Mahr, Karoly; Schenker, Michael; Sohn, Joo Hyuk; Lee, Keun Seok; Sarker, Shah-Jalal; Coetzee, Carike; Mousa, Kelly; Castan, Javier Cortes

MEDICINE PRICES DISPARITY AMONG RETAIL PHARMACIES IN SELANGOR, MALAYSIA

VALUE IN HEALTH

IF6

2017-10-01

OAAI

Lim, Y. W.; Neoh, C. F.; Lee, K. S.; Tan, C. S.; Khan, T. M.; Long, C. M.

Clinical application of multimodal fluorescent-radioactive system in advanced breast cancer patients with neoadjuvant therapy; interim analysis for 65 patients

CANCER RESEARCH

IF16.6

2017-02-15

PREAI

Lee, S.; Jung, S-Y; Kim, S-K; Lee, E. S.; Lee, M. H.; Park, S. J.; Kang, H-S; Lee, Ks; Park, I. H.; Sim, S. H.; Kim, Y.; Kwon, Y.; Joo, J.; Kang, S. H.

The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

CANCER RESEARCH

IF16.6

2017-02-15

PREAI

Park, I. H.; Im, S-A; Jung, K. H.; Sohn, J. H.; Park, Y. H.; Park, K-H; Nam, B-H; Kim, J. H.; Kim, H-J; Lee, S.; Kim, T-Y; Lee, K-H; Kim, S-B; Lee, K. S.; Ro, J.

Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer

CANCER RESEARCH

IF16.6

2017-02-15

PREAI

Cho, J. N.; Song, E. J.; Lee, M. H.; Jung, S-Y; Lee, S.; Kang, H-S; Sim, S. H.; Park, I. H.; Lee, K. S.; Kim, Y. J.; Kim, S-K; Kwon, Y.; Nam, B-H; Lee, E. S.

DO PHARMACEUTICAL COST CONTROL POLICIES EFFECTIVE IN REDUCING PHARMACEUTICAL EXPENDITURE AND VOLUME? A SYSTEMATIC REVIEW

VALUE IN HEALTH

IF6

2016-11-01

OAAI

Lee, K. S.; Hendrie, D.; Sunderland, B.; Moorin, R. E.

TRANS-PACIFIC PARTNERSHIP AGREEMENT AND ITS IMPACT ON ACCESSIBILITY AND AFFORDABILITY OF MEDICINES: A META-SYNTHESIS

VALUE IN HEALTH

IF6

2016-11-01

OAAI

Yap, Y. Y.; Wong, C. P.; Khan, T. M.; Lee, K. S.; Ming, L. C.

Does participation in clinical trials influence on survival in patients with metastatic breast cancer?

CANCER RESEARCH

IF16.6

2016-02-15

PREAI

Kim, T-Y; Sohn, J. H.; Kim, S-B; Yoon, J. H.; Kim, G. M.; Lee, K. H.; Koh, S-J; Park, Y. H.; Lee, S. E.; Chae, Y.; Lee, K. S.; Lee, K. E.; Won, H. S.; Kim, J. H.; Jeong, J.; Park, K. H.; Cho, E. K.; Im, Y-H; Im, S-A; Jung, K. H.

The oncologic effect of a gonadotropin releasing hormone (GnRH) agonist for ovarian protection during breast cancer chemotherapy

CANCER RESEARCH

IF16.6

2016-02-15

PREAI

Kim, H. J.; Lee, M. H.; Lee, J. E.; Park, S. H.; Lee, E. S.; Kang, Y-J; Lee, J. H.; Shin, H. N.; Kim, S. I.; Im, S. A.; Ahn, S. H.; Lee, K. S.; Sohn, J.; Han, W.; Nam, S. J.

Role of endocrine therapy in premenopausal patients with hormone receptor-positive metastatic breast cancer, compared with postmenopausal patients: Diachronic analyses from nationwide cohort in Korea (KCSG BR 14-07)

CANCER RESEARCH

IF16.6

2016-02-15

PREAI

Kim, T-Y; Ahn, J-H; Yoon, J. H.; Sohn, J. H.; Kim, G. M.; Lee, K. H.; Park, Y. H.; Koh, S-J; Lee, S. E.; Chae, Y.; Lee, K. S.; Lee, K. E.; Won, H. S.; Kim, J. H.; Jeong, J.; Park, K. H.; Cho, E. K.; Im, Y-H; Im, S-A; Jung, K. H.

A prospective, open-label, single-arm, multi-center, phase II exploratory study to evaluate the efficacy and safety of poziotinib (NOV120101) in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens

CANCER RESEARCH

IF16.6

2016-02-15

PREAI

Park, Y-H; Jung, K. H.; Sohn, J. H.; Lee, K. S.; Lee, K. H.; Kim, J-H; Kim, J-Y; Jung, J.; Han, H.; Park, W-Y; Im, S-A

The role of skeletal muscle volume on prognosis of breast cancer survivors using with cross-sectional image

CANCER RESEARCH

IF16.6

2016-02-15

PREAI

Song, E. J.; Park, S. J.; Lee, M. H.; Kwon, Y.; Ko, K. L.; Lee, K. S.; Ro, J.; Jung, S. Y.; Lee, S. Y.; Kang, H. S.; Lee, E. S.

Clinical effectiveness of everolimus and exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIlb EVEREXES study

CANCER RESEARCH

IF16.6

2016-02-15

PREAI

Im, Y-H; Uslu, R.; Lee, K. S.; Nagarkar, R.; Sohn, J.; Sevinc, A.; Altundag, K.; Chang, Y-C; Abdel-Razeq, H.; Im, S-A; Jeong, J.; Park, H. Y.; Arpornwirat, W.; Bastick, P.; Le, T. H.; Arikan, O. Ocak; Xue, H. L.; Canatar, A.; Valenti, R.; Kim, S-B

CKAP2 (cytoskeleton associated protein 2) is a new prognostic marker in HER2-negative luminal breast cancer

CANCER RESEARCH

IF16.6

2016-02-15

PREAI

Sim, S. H.; Bae, C-D; Kwon, Y.; Park, I. H.; Lee, K. S.; Jung, S-Y; Lee, S.; Kang, H-S; Lee, E. S.; Kim, H-S; Hong, K-M; Ro, J.

The PROCEED trial KCSG BR11-01: Phase III multicenter randomized open label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

CANCER RESEARCH

IF16.6

2013-12-15

PREAI

Park, I. H.; Lee, K. S.; Im, S-A; Jung, K. H.; Park, K. H.; Im, Y-H; Lee, S.; Kim, Y. J.; Kim, H-J; Lee, S.; Lee, M. H.; Kim, T-Y; Lee, K-H; Kim, S-B; Ahn, J-H; Nam, B-H; Ro, J.

研究方向